Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,317 papers from all fields of science
Search
Sign In
Create Free Account
refractory hairy cell leukemia
Known as:
Hairy Cell Leukemia, Refractory
, leukemia, hairy cell, recurrent
, recurrent hairy cell leukemia
Expand
Hairy cell leukemia that is resistant to treatment.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
18 relations
Atypical lymphocyte
B lymphoblast
B-Lymphocytes
BRAF gene
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
R. Kreitman
,
C. Dearden
,
+14 authors
F. Giles
Blood
2019
Corpus ID: 209264651
Moxetumomab pasudotox-tdfk is a first-in-class recombinant CD22-directed cytotoxin approved in the US for the treatment of adult…
Expand
2018
2018
Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and…
Denison Kuruvilla
,
Y. Chia
,
+9 authors
L. Roskos
2018
Corpus ID: 59171173
7060Background: Moxe is an immunotoxin targeting CD22 on B cells leading to cell death. The objectives of this analysis were to…
Expand
Review
2015
Review
2015
Immunoconjugates in the management of hairy cell leukemia.
R. Kreitman
,
I. Pastan
Baillière's Best Practice & Research: Clinical…
2015
Corpus ID: 13779013
2014
2014
Treatment of Refractory Hairy Cell Leukemia with a BRAF-inhibitor: Lessons to be Learnt
Eszter Sári
,
Z. Nagy
,
+7 authors
J. Demeter
Pathology and Oncology Research
2014
Corpus ID: 16581793
Hairy cell leukemia is a rare chronic lymphoproliferative disorder with indolent but progressive clinical course. Patients…
Expand
2012
2012
Targeted immunotherapy for hairy cell leukemia.
Jae H. Park
,
R. Levine
Journal of Clinical Oncology
2012
Corpus ID: 207031417
In Journal of Clinical Oncology, Kreitman et al report the efficacy of anti-CD22 monoclonal antibody (mAb) conjugated to…
Expand
Review
2011
Review
2011
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
R. Kreitman
,
E. Arons
,
M. Stetler-Stevenson
,
D. FitzGerald
,
W. Wilson
,
I. Pastan
Leukemia and Lymphoma
2011
Corpus ID: 24250833
Standard treatment for hairy cell leukemia (HCL) is markedly effective, but the constant decrease in disease-free survival…
Expand
2010
2010
A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results
R. Kreitman
,
M. Tallman
,
+8 authors
I. Pastan
2010
Corpus ID: 78186140
Abstract 2516 Currently no adequate therapies exist for patients with refractory hairy cell leukemia (HCL). The CD22 antigen is…
Expand
Review
2006
Review
2006
Immunotoxins in the treatment of refractory hairy cell leukemia.
R. Kreitman
,
I. Pastan
Hematology/Oncology Clinics of North America
2006
Corpus ID: 23454884
2005
2005
[Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress].
M. Makita
,
Koji Nakamura
,
A. Kono
[Rinsho ketsueki] The Japanese journal of…
2005
Corpus ID: 25588341
A 69-year-old man was referred to our hospital because of thrombocytopenia and was diagnosed as having hairy cell leukemia…
Expand
2004
2004
Successful Induction of Long-Term Remission Using Rituximab in a Patient with Refractory Hairy Cell Leukemia—Japanese Variant
Tomoyuki Imamura
,
E. Ohtsuka
,
+4 authors
M. Nasu
International journal of hematology
2004
Corpus ID: 20172586
We report the case of a 76-year-old man with hairy cell leukemia (HCL)-Japanese variant who underwent rituximab therapy. HCL…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE